Properties (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Sana_Cell_Therapy
gptkb:Sana_Therapeutics |
| gptkbp:CEO |
Steve_Harr
|
| gptkbp:clinicalTrials |
gptkb:Asia
gptkb:United_States Cancer Europe Genetic disorders Autoimmune diseases Phase 1 Phase 2 |
| gptkbp:collaborations |
Academic institutions
Research organizations |
| gptkbp:communityEngagement |
Patient advocacy groups
Healthcare_professionals |
| gptkbp:employees |
Over 100
|
| gptkbp:focus |
Cell therapy
Gene therapy |
| gptkbp:founded |
2018
|
| gptkbp:founder |
Steve_Harr
|
| gptkbp:funding |
Venture capital
Public offerings |
| gptkbp:headquarters |
gptkb:Seattle,_Washington
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sana Biotechnology
|
| gptkbp:investmentFocus |
$100 million
$200 million |
| gptkbp:leadership |
Executive Team
Board_of_Directors |
| gptkbp:mission |
Transform lives through cell and gene therapy.
|
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
Research institutions Novartis Biopharmaceutical companies |
| gptkbp:patentCitation |
Cell engineering methods
Gene therapy technologies Therapeutic_applications |
| gptkbp:products |
Clinical programs
Preclinical programs Therapeutic_candidates |
| gptkbp:regulatoryCompliance |
gptkb:FDA
EMA |
| gptkbp:researchAreas |
Oncology
Neurology Rare diseases |
| gptkbp:scientificName |
Industry experts
Academic leaders |
| gptkbp:stockSymbol |
SANA
|
| gptkbp:sustainabilityInitiatives |
Social responsibility
Environmental responsibility Governance practices |
| gptkbp:technology |
Cell engineering
Engineered cells Gene_editing |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:type |
Public Company
|
| gptkbp:vision |
Developing a new generation of medicines.
|
| gptkbp:website |
https://sanabiotechnology.com
|